Loading data for CNSP — first visit, this takes a few seconds.
CNS Pharmaceuticals, Inc.
5.73 -0.16 (-2.72%)
5.78 -1.03%
- Capitalisation boursière
- $8.53M
- Volume
- 4.75K
CNS Pharmaceuticals, Inc. (CNSP) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | $0 | n/a | n/a |
| EPS | -$0.38 | -$0.14 | +94.08% |
Métriques
- Cours acheteur
- 4.04
- Capitalisation boursière
- 8.53M
- Résultat net (ttm)
- -16.7M
- 1.00
- -15.39
- n/a
- -14.97
- P/B (ttm)
- 0.47
- P/S (ttm)
- n/a
- Date des résultats
- n/a
- Cours vendeur
- 7.68
- Volume
- 4,746
- Volume moy. (20D)
- 10,777
- Ouverture
- 5.90
- Clôture précédente
- 5.89
- Fourchette du jour
- 5.73 - 5.90
- Intervalle de 52 semaines
- 1.90 - 10.59
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de CNS Pharmaceuticals, Inc.
Voir le profil →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Nov 8, 2019
Employés 8
Bourse NasdaqCM
Symbole boursier CNSP
Site web https://cnspharma.com